OHSU Pilot Finds Time-Restricted Eating Feasible With Biomarker Shifts in Early Huntington's

The study measured adherence via food logs, weight stability, Unified Huntington's Disease Rating Scale total motor score, and plasma neurofilament light chain as a marker of neuronal injury. Participants chose their own windows, typically midday to evening, and were instructed to keep caloric intake unchanged. No serious adverse events occurred, but the design lacked randomization or a control arm, leaving open the possibility that observed changes reflect expectation or natural fluctuation rather than the intervention itself.

Prior mouse work on intermittent fasting in Huntington's models activated autophagy and mitochondrial biogenesis pathways that overlap with those targeted by emerging disease-modifying compounds. Human data remain sparse; one prior observational study linked higher meal frequency to faster functional decline, yet no interventional trial had tested circadian-aligned eating until this pilot. The absence of a caloric deficit distinguishes the protocol from classic intermittent fasting regimens used for weight loss and may explain preserved body mass despite the neurodegenerative cachexia common in Huntington's.

Next steps require a multicenter randomized controlled trial powered for clinical endpoints, with at least 12 months of follow-up and stratification by CAG repeat length. Such a trial would also need to incorporate continuous glucose monitoring and actigraphy to test whether metabolic and sleep improvements mediate any neurological signal. Regulatory interest will hinge on whether surrogate biomarker changes translate into slowed progression on the Total Functional Capacity scale.